Piper Jaffray Remains Sidelined on Trovagene (TROV) Following 2Q Miss
Tweet Send to a Friend
Piper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $4.00 (from $5.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
